{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:44:54Z","timestamp":1789587894237,"version":"build-2803163510"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"ICMR","doi-asserted-by":"publisher","award":["3\/1\/3\/BRET-2024\/HRD (L1)"],"award-info":[{"award-number":["3\/1\/3\/BRET-2024\/HRD (L1)"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology","doi-asserted-by":"publisher","award":["DBTHRDPMU\/JRF\/BET-24\/I\/2024-25\/376"],"award-info":[{"award-number":["DBTHRDPMU\/JRF\/BET-24\/I\/2024-25\/376"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"CSIR","doi-asserted-by":"publisher","award":["24 J\/01\/00130"],"award-info":[{"award-number":["24 J\/01\/00130"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.molimm.2026.08.008","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:55:40Z","timestamp":1786618540000},"page":"98-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["iPSC-derived polyvalent vaccines as ontogenetically informed immunogens toward overcoming immune refractoriness in microsatellite-stable colorectal cancer: An emerging frontier in cancer immunotherapy"],"prefix":"10.1016","volume":"198","author":[{"given":"Abhishek","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyumn","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesavaperumal","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Rahamathulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Muqtader","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandralekha","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewang","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randhir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uddalak","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2026.08.008_bib1","unstructured":"A Phase 1\/2 Trial of Dual Administration of Intraperitoneal and Intravenous TROP2-Directed CAR-NK with TGFBR2 Knockout Therapy for Colorectal Cancer-Related Peritoneal Carcinomatosis (Chip-CRC Trial) [Internet]. ClinicalTrials.gov; 2026 [cited 2026 Jul 26]. Report No.: NCT07411599. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07411599."},{"key":"10.1016\/j.molimm.2026.08.008_bib2","doi-asserted-by":"crossref","unstructured":"Ai H., Yang H., Li L., et al. Cancer\/testis antigens: promising immunotherapy targets for digestive tract cancers. Front Immunol [Internet]. 2023 [cited 2025 Nov 12];14.","DOI":"10.3389\/fimmu.2023.1190883"},{"issue":"9","key":"10.1016\/j.molimm.2026.08.008_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103669","article-title":"Immunotherapy and immunoevasion of colorectal cancer","volume":"28","author":"Al Zein","year":"2023","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.molimm.2026.08.008_bib4","first-page":"12","article-title":"Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects","volume":"12","author":"Alidadi","year":"2024","journal-title":"Front. Cell. Dev. Biol. [Internet]"},{"issue":"13","key":"10.1016\/j.molimm.2026.08.008_bib5","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/jcm12134301","article-title":"Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.molimm.2026.08.008_bib6","unstructured":"Analysis of Cost of Cell Therapy Manufacturing: Autologous Cell Therapies, Part 1 [Internet]. BioProcess International. [cited 2026 Jul 26]. Available from: https:\/\/www.bioprocessintl.com\/cell-therapies\/cost-analysis-of-cell-therapy-manufacture-autologous-cell-therapies-part-1."},{"issue":"42","key":"10.1016\/j.molimm.2026.08.008_bib7","first-page":"1","article-title":"Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability\/Mismatch Repair Deficiency in 2022","author":"Andr\u00e9","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"7435","key":"10.1016\/j.molimm.2026.08.008_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature11807","article-title":"Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells","volume":"494","author":"Araki","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.molimm.2026.08.008_bib9","first-page":"251","article-title":"Induced Pluripotent Stem Cells (iPSCs): The Ethical Alternative?","volume":"7","author":"Arifa","year":"2024","journal-title":"Stem Cell. Res. Regen. Med."},{"key":"10.1016\/j.molimm.2026.08.008_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115134","article-title":"Hypoimmunogenic pluripotent stem cells: A game-changer in cell-based regenerative medicine","volume":"162","author":"Asadi-Sarabi","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.molimm.2026.08.008_bib11","doi-asserted-by":"crossref","unstructured":"Assessing Tumorigenicity in Stem Cell-Derived Therapeutic Products: A Critical Step in Safeguarding Regenerative Medicine. Bioengineering (Basel). 2023;10(7):857. doi:10.3390\/bioengineering10070857.","DOI":"10.3390\/bioengineering10070857"},{"issue":"3","key":"10.1016\/j.molimm.2026.08.008_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/jcm8030288","article-title":"iPS-Cell Technology and the Problem of Genetic Instability\u2014Can It Ever Be Safe for Clinical Use?","volume":"8","author":"Attwood","year":"2019","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib13","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s12094-024-03667-2","article-title":"Emerging immunologic approaches as cancer anti-angiogenic therapies","volume":"27","author":"Azimi","year":"2025","journal-title":"Clin. Transl. Oncol."},{"issue":"9","key":"10.1016\/j.molimm.2026.08.008_bib14","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1021\/acsnano.3c04471","article-title":"A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists","volume":"18","author":"Baljon","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.molimm.2026.08.008_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01616412.2025.2600434","article-title":"Engineering brain organoids and organ-on-chip systems for modeling neurodevelopmental and neurodegenerative pathophysiology","author":"Banerjee","year":"2025","journal-title":"Neurol. Res."},{"key":"10.1016\/j.molimm.2026.08.008_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc3034","article-title":"The tumorigenicity of human embryonic and induced pluripotent stem cells","volume":"11","author":"Ben-David","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.molimm.2026.08.008_bib18","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.3390\/cancers12123581","article-title":"Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines","volume":"12","author":"Bernardes de Jesus","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.molimm.2026.08.008_bib19","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1097\/MJT.0b013e3182068cdb","article-title":"Therapeutic Cancer Vaccines: The Latest Advancement in Targeted Therapy","volume":"19","author":"Bilusic","year":"2012","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.molimm.2026.08.008_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/10732748231202470","article-title":"Comparative Analysis of First-Line FOLFOX Treatment With and Without Anti-VEGF Therapy in Metastatic Colorectal Carcinoma: A Real-World Data Study","volume":"30","author":"Brenner","year":"2023","journal-title":"Cancer Control."},{"issue":"5","key":"10.1016\/j.molimm.2026.08.008_bib21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.stemcr.2022.03.019","article-title":"Functional genomics and the future of iPSCs in disease modeling","volume":"17","author":"Brooks","year":"2022","journal-title":"Stem Cell. Rep."},{"issue":"3","key":"10.1016\/j.molimm.2026.08.008_bib22","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/sj.bjc.6600081","article-title":"Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma","volume":"86","author":"Budach","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molimm.2026.08.008_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.16047","article-title":"EMA commentary on the guideline on quality, nonclinical and clinical aspects of medicinal products containing genetically modified cells","author":"Celis","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","article-title":"Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications","volume":"9","author":"Cerneckis","year":"2024","journal-title":"Sig Transduct. Target. Ther."},{"key":"10.1016\/j.molimm.2026.08.008_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12943-023-01873-0","article-title":"Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.molimm.2026.08.008_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104775","article-title":"Immunotherapy in microsatellite-stable colorectal cancer: Strategies to overcome resistance","volume":"212","author":"Chen","year":"2025","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"5","key":"10.1016\/j.molimm.2026.08.008_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc7609","article-title":"Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy","volume":"7","author":"Cheng","year":"2021","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.molimm.2026.08.008_bib28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4236\/jct.2023.146022","article-title":"Exploration of Kras Mutations and Their Potential for Being a Target Molecule in Cancer Chemotherapy","volume":"14","author":"Chinthareddy","year":"2023","journal-title":"J. Cancer Ther."},{"issue":"8","key":"10.1016\/j.molimm.2026.08.008_bib29","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2022016205","article-title":"Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies","volume":"141","author":"Cichocki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2026.08.008_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2019.12.005","article-title":"Cross-presentation of exogenous antigens on MHC I molecules","volume":"64","author":"Colbert","year":"2020","journal-title":"Curr. Opin. Immunol."},{"issue":"8","key":"10.1016\/j.molimm.2026.08.008_bib31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14760584.2018.1506332","article-title":"Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy","volume":"17","author":"Collins","year":"2018","journal-title":"Expert. Rev. Vaccin."},{"key":"10.1016\/j.molimm.2026.08.008_bib32","unstructured":"Colorectal Cancer Survival Rates | Colorectal Cancer Prognosis [Internet]. [cited 2025 Nov 11]. Available from: https:\/\/www.cancer.org\/cancer\/types\/colon-rectal-cancer\/detection-diagnosis-staging\/survival-rates.html."},{"key":"10.1016\/j.molimm.2026.08.008_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1021905","article-title":"Current GMP standards for the production of vaccines and antibodies: An overview","volume":"10","author":"Covarrubias","year":"2022","journal-title":"Front. Public. Health"},{"key":"10.1016\/j.molimm.2026.08.008_bib34","first-page":"11","article-title":"Prophylactic Cancer Vaccines Engineered to Elicit Specific Adaptive Immune Response","volume":"11","author":"Crews","year":"2021","journal-title":"Front. Oncol. [Internet]"},{"issue":"2","key":"10.1016\/j.molimm.2026.08.008_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/pharmaceutics12020092","article-title":"Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells\u2014An Update","volume":"12","author":"D\u00f6rrie","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.molimm.2026.08.008_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2025.100213","article-title":"Generative AI for drug discovery and protein design: the next frontier in AI-driven molecular science","volume":"27","author":"Das","year":"2025","journal-title":"Med. Drug Discov."},{"issue":"36","key":"10.1016\/j.molimm.2026.08.008_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202502448","article-title":"Transforming Precision Medicine through Generative AI: Advanced Architectures and Tailored Therapeutic Design for Patient\u2010Specific Drug Discovery","volume":"10","author":"Das","year":"2025","journal-title":"ChemistrySelect"},{"issue":"2","key":"10.1016\/j.molimm.2026.08.008_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.vacun.2025.500391","article-title":"Bibliometric analysis of circular RNA cancer vaccines and their emerging impact","volume":"26","author":"Das","year":"2025","journal-title":"Vacunas"},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cpt.2024.11.003","article-title":"Circular RNA vaccines: Pioneering the next-gen cancer immunotherapy","volume":"3","author":"Das","year":"2024","journal-title":"Cancer Pathog. Ther."},{"issue":"8","key":"10.1016\/j.molimm.2026.08.008_bib40","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1007\/s00432-022-04440-0","article-title":"Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy","volume":"149","author":"Davern","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.molimm.2026.08.008_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202300121","article-title":"Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell\/tissue Lysate or Whole Tumor Cell","volume":"10","author":"Diao","year":"2023","journal-title":"Adv. Sci."},{"issue":"5","key":"10.1016\/j.molimm.2026.08.008_bib42","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1128\/IAI.01328-06","article-title":"Th1 and Th2 Cells Help CD8 T-Cell Responses","volume":"75","author":"Ekkens","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.molimm.2026.08.008_bib43","unstructured":"Elicio Therapeutics. First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors [Internet]. clinicaltrials.gov; 2025 [cited 2025 Nov 16]. Report No.: NCT04853017. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04853017."},{"key":"10.1016\/j.molimm.2026.08.008_bib44","doi-asserted-by":"crossref","unstructured":"Elkoshi Z. On the Prognostic Power of Tumor-Infiltrating Lymphocytes \u2013 A Critical Commentary. Front Immunol [Internet]. 2022 [cited 2025 Nov 16];13.","DOI":"10.3389\/fimmu.2022.892543"},{"key":"10.1016\/j.molimm.2026.08.008_bib45","volume":"13","author":"El-Mesallamy","year":"2018"},{"key":"10.1016\/j.molimm.2026.08.008_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154183","article-title":"Insights on the potential oncogenic impact of long non-coding RNA nicotinamide nucleotide transhydrogenase antisense RNA 1 in different cancer types; integrating pathway(s) and clinical outcome(s) association","volume":"240","author":"El-Sheikh","year":"2022","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.molimm.2026.08.008_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154570","article-title":"LncRNA NNT-AS1\/hsa-miR-485\u20135p\/HSP90 axis in-silico and clinical prospect correlated-to histologic grades-based CRC stratification: A step toward ncRNA Precision","volume":"247","author":"El-Sheikh","year":"2023","journal-title":"Pathol. - Res. Pract."},{"issue":"6","key":"10.1016\/j.molimm.2026.08.008_bib48","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/vaccines13060588","article-title":"Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity","volume":"13","author":"Eslami","year":"2025","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.molimm.2026.08.008_bib49","unstructured":"European Medicines Agency. Guideline on Human Cell-Based Medicinal Products (EMEA\/CHMP\/410869\/2006). London: EMA; 2008a. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-human-cell-based-medicinal-products_en.pdf."},{"key":"10.1016\/j.molimm.2026.08.008_bib50","unstructured":"European Medicines Agency. Guideline on Safety and Efficacy Follow-up and Risk Management of Advanced Therapy Medicinal Products (EMA\/149995\/2008). London: EMA; 2008b."},{"key":"10.1016\/j.molimm.2026.08.008_bib51","doi-asserted-by":"crossref","unstructured":"Fang M., Allen A., Luo C., et al. Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy. Front Immunol [Internet]. 2024 [cited 2025 Nov 17];15.","DOI":"10.3389\/fimmu.2024.1457629"},{"key":"10.1016\/j.molimm.2026.08.008_bib52","unstructured":"Fate Therapeutics, Inc. Fate Therapeutics Announces FDA Clearance for FT536, a First-in-Class MICA\/B-Targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors [Internet]. 2022 [cited 2026 Jul 26]. Available from: https:\/\/ir.fatetherapeutics.com\/news-releases\/news-release-details\/fate-therapeutics-announces-fda-clearance-ft536-first-class."},{"issue":"6","key":"10.1016\/j.molimm.2026.08.008_bib53","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.molimm.2026.08.008_bib54","first-page":"2261","article-title":"Correlation of the Pro-Inflammatory Cytokines IL-1\u03b2, IL-6, and TNF-\u03b1, Inflammatory Markers, and Tumor Markers with the Diagnosis and Prognosis of Colorectal Cancer","volume":"13","author":"Florescu","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.molimm.2026.08.008_bib55","unstructured":"From cold to hot tumors: feasibility of applying therapeutic insights to TNBC - PMC [Internet]. [cited 2025 Nov 12]. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12540225\/."},{"key":"10.1016\/j.molimm.2026.08.008_bib56","unstructured":"Frontiers | Defining Memory CD8 T Cell [Internet]. [cited 2025 Nov 11]. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2018.02692\/full."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12967-024-06033-6","article-title":"mRNA vaccines in the context of cancer treatment: from concept to application","volume":"23","author":"Fu","year":"2025","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.molimm.2026.08.008_bib58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/vaccines8020147","article-title":"Novel Genetic Melanoma Vaccines Based on Induced Pluripotent Stem Cells or Melanosphere-Derived Stem-Like Cells Display High Efficacy in a murine Tumor Rejection Model","volume":"8","author":"G\u0105bka-Buszek","year":"2020","journal-title":"Vaccin. (Basel)"},{"issue":"15","key":"10.1016\/j.molimm.2026.08.008_bib59","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.3390\/cancers17152582","article-title":"Therapeutic Cancer Vaccines in Colorectal Cancer: Platforms, Mechanisms, and Combinations","volume":"17","author":"Gallio","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib60","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0952-7915(00)00191-6","article-title":"Danger signals: SOS to the immune system","volume":"13","author":"Gallucci","year":"2001","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molimm.2026.08.008_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1161048","article-title":"The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives","volume":"13","author":"Gandini","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.molimm.2026.08.008_bib62","unstructured":"Genetic Adjuvants Interleukin-12 and Granulocyte-Macrophage Colony Stimulating Factor Enhance the Immunogenicity of an Ebola Virus Deoxyribonucleic Acid Vaccine in Mice | The Journal of Infectious Diseases | Oxford Academic [Internet]. [cited 2025 Nov 15]. Available from: https:\/\/academic.oup.com\/jid\/article\/218\/suppl_5\/S519\/5056373."},{"issue":"5","key":"10.1016\/j.molimm.2026.08.008_bib63","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3390\/cancers16051029","article-title":"Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment","volume":"16","author":"Gmeiner","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib64","doi-asserted-by":"crossref","DOI":"10.1007\/s10142-026-01890-4","article-title":"Multiscale predictive cellular modeling: integrating hypothesis grammars, digital twins, and multi-omics for In silico oncology and precision theranostics","volume":"26","author":"Gopukumar","year":"2026","journal-title":"Funct. Integr. Genom."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib65","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Sig Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.molimm.2026.08.008_bib66","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/s41590-024-01974-y","article-title":"AI and immunology as a new research paradigm","volume":"25","author":"Gururaj","year":"2024","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.molimm.2026.08.008_bib67","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cancers13020210","article-title":"The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.molimm.2026.08.008_bib68","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4161\/hv.20740","article-title":"Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer","volume":"8","author":"Hanna, Jr","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.70030","article-title":"Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities","volume":"14","author":"Hartley","year":"2025","journal-title":"Clin. & Transl. Immunol."},{"key":"10.1016\/j.molimm.2026.08.008_bib70","article-title":"Addressing the rising colorectal cancer burden in the older adult: examining modifiable risk and protective factors for comprehensive prevention strategies","volume":"15","author":"He","year":"2025","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.molimm.2026.08.008_bib71","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s12015-023-10633-y","article-title":"Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors","volume":"19","author":"He","year":"2023","journal-title":"Stem Cell. Rev. Rep."},{"issue":"3","key":"10.1016\/j.molimm.2026.08.008_bib72","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/ph16030392","article-title":"Current Trends in Neoantigen-Based Cancer Vaccines","volume":"16","author":"Ho","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.molimm.2026.08.008_bib73","first-page":"A230","article-title":"Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors","volume":"8","author":"Hong","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.molimm.2026.08.008_bib74","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2567.2006.02452.x","article-title":"CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes","volume":"120","author":"Huang","year":"2007","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib75","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41541-024-00881-5","article-title":"Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers","volume":"9","author":"Huang","year":"2024","journal-title":"npj Vaccin."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib76","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40164-025-00662-3","article-title":"Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines","volume":"14","author":"Hushmandi","year":"2025","journal-title":"Exp. Hematol. & Oncol."},{"key":"10.1016\/j.molimm.2026.08.008_bib77","unstructured":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets | Journal of Hematology & Oncology | Full Text [Internet]. [cited 2025 Nov 15]. Available from: https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01282-8."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib78","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/cancers10010026","article-title":"Colorectal Cancers: An Update on Their Molecular Pathology","volume":"10","author":"Inamura","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.molimm.2026.08.008_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.942235","article-title":"Colorectal cancer vaccines: The current scenario and future prospects","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2026.08.008_bib80","article-title":"Immunogenic Cell Death-Based Cancer Vaccines","volume":"12","author":"Jin","year":"2021","journal-title":"Front. Immunol. [Internet]"},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib81","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1186\/s12967-025-07115-9","article-title":"New power in cancer immunotherapy: the rise of chimeric antigen receptor macrophage (CAR-M)","volume":"23","author":"Jing","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib82","doi-asserted-by":"crossref","first-page":"27","DOI":"10.18609\/vac.2025.005","article-title":"The Promise and Predicament of Combining Adjuvants in Vaccines","volume":"4","author":"Joffe","year":"2025","journal-title":"Vaccin. Insights"},{"issue":"12","key":"10.1016\/j.molimm.2026.08.008_bib83","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.7150\/thno.111400","article-title":"Dual prophylactic and therapeutic potential of iPSC-based vaccines and neoantigen discovery in colorectal cancer","volume":"15","author":"Jwo","year":"2025","journal-title":"Theranostics"},{"issue":"17","key":"10.1016\/j.molimm.2026.08.008_bib84","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/cells12172159","article-title":"Cancer Vaccine Therapeutics: Limitations and Effectiveness\u2014A Literature Review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib85","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.stem.2013.03.008","article-title":"To Be Immunogenic, or Not to Be: That\u2019s the iPSC Question","volume":"12","author":"Kaneko","year":"2013","journal-title":"Cell. Stem Cell."},{"key":"10.1016\/j.molimm.2026.08.008_bib86","unstructured":"Kankanala V.L., Zubair M., Mukkamalla S.K.R. Carcinoembryonic Antigen. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 11]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK578172\/."},{"key":"10.1016\/j.molimm.2026.08.008_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2022.102172","article-title":"Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics","volume":"70","author":"Kaur","year":"2022","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.molimm.2026.08.008_bib88","article-title":"Activated B-Cells enhance epitope spreading to support successful cancer immunotherapy","volume":"15","author":"Kellermann","year":"2024","journal-title":"Front. Immunol. [Internet]"},{"key":"10.1016\/j.molimm.2026.08.008_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116049","article-title":"Camptothecin structure simplification elaborated new imidazo[2,1-b]quinazoline derivative as a human topoisomerase I inhibitor with efficacy against bone cancer cells and colon adenocarcinoma","volume":"265","author":"Khodair","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.molimm.2026.08.008_bib90","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/gm291","article-title":"Embryonic stem cell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine","volume":"3","author":"Kim","year":"2011","journal-title":"Genome Med."},{"key":"10.1016\/j.molimm.2026.08.008_bib91","article-title":"Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy","volume":"8","author":"Kishi","year":"2021","journal-title":"Front. Med. [Internet]"},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib92","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.stem.2018.01.016","article-title":"Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo","volume":"22","author":"Kooreman","year":"2018","journal-title":"Cell. Stem Cell."},{"issue":"22","key":"10.1016\/j.molimm.2026.08.008_bib93","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/cancers13225789","article-title":"The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma","volume":"13","author":"Krog","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib94","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4240\/wjgs.v15.i4.495","article-title":"Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review","volume":"15","author":"Kumar","year":"2023","journal-title":"World J. Gastrointest. Surg."},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib95","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/vaccines5040034","article-title":"TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis","volume":"5","author":"Kuzmich","year":"2017","journal-title":"Vaccin. (Basel)"},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib96","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43556-024-00241-8","article-title":"Cancer vaccines: platforms and current progress","volume":"6","author":"Lei","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.molimm.2026.08.008_bib97","doi-asserted-by":"crossref","unstructured":"Liu X., Yan G., Xu B., et al. Evaluating the role of IDO1 macrophages in immunotherapy using scRNA-seq and bulk-seq in colorectal cancer. Front Immunol [Internet]. 2022b [cited 2025 Nov 15];13.","DOI":"10.3389\/fimmu.2022.1006501"},{"issue":"15","key":"10.1016\/j.molimm.2026.08.008_bib98","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.7150\/ijbs.76281","article-title":"Engineering neoantigen vaccines to improve cancer personalized immunotherapy","volume":"18","author":"Liu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.molimm.2026.08.008_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188447","article-title":"Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside","volume":"1874","author":"Lizardo","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.molimm.2026.08.008_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.nwnano.2024.100058","article-title":"Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations","volume":"8","author":"M\u00e1rquez","year":"2024","journal-title":"Nano Trends"},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib101","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.immuni.2024.03.002","article-title":"DAMPs and DAMP-sensing receptors in inflammation and diseases","volume":"57","author":"Ma","year":"2024","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.molimm.2026.08.008_bib102","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5306\/wjco.v14.i2.81","article-title":"Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review","volume":"14","author":"Ma","year":"2023","journal-title":"World J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.molimm.2026.08.008_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.88","article-title":"Autologous Induced Pluripotent Stem Cell-Based Cell Therapies: Promise, Progress, and Challenges","volume":"1","author":"Madrid","year":"2021","journal-title":"Curr. Protoc."},{"issue":"11","key":"10.1016\/j.molimm.2026.08.008_bib104","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jcyt.2024.05.022","article-title":"Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee","volume":"26","author":"Madrid","year":"2024","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib105","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad030","article-title":"Cancer vaccines: from an immunology perspective","volume":"4","author":"Makker","year":"2024","journal-title":"Immunother. Adv."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib106","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/jcm13010040","article-title":"Colorectal Cancer: Current Updates and Future Perspectives","volume":"13","author":"Marcellinaro","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.molimm.2026.08.008_bib107","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41541-023-00801-z","article-title":"MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans","volume":"9","author":"Mayer","year":"2024","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.molimm.2026.08.008_bib108","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3389\/fimmu.2020.01067","article-title":"vivo Imaging Technologies to Monitor the Immune System","volume":"11","author":"McCarthy","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.molimm.2026.08.008_bib109","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3390\/vaccines13070689","article-title":"Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities","volume":"13","author":"Muthukutty","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.molimm.2026.08.008_bib110","doi-asserted-by":"crossref","unstructured":"Nemunaitis J., Stanbery L., Walter A., et al. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy. Future Oncol. 20(29):2149\u20132164.","DOI":"10.1080\/14796694.2024.2376518"},{"issue":"16_","key":"10.1016\/j.molimm.2026.08.008_bib111","article-title":"AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer","volume":"41","author":"O\u2019Reilly","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2026.08.008_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.mimet.2024.106998","article-title":"Leveraging artificial intelligence in vaccine development: A narrative review","volume":"224","author":"Olawade","year":"2024","journal-title":"J. Microbiol. Methods"},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib113","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","article-title":"CD4 and CD8 T lymphocyte interplay in controlling tumor growth","volume":"75","author":"Ostroumov","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.molimm.2026.08.008_bib114","article-title":"Induced Pluripotent Stem Cell-Based Cancer Vaccines","volume":"10","author":"Ouyang","year":"2019","journal-title":"Front. Immunol. [Internet]"},{"issue":"6","key":"10.1016\/j.molimm.2026.08.008_bib115","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.stemcr.2021.04.004","article-title":"Antitumor effects of iPSC-based cancer vaccine in pancreatic cancer","volume":"16","author":"Ouyang","year":"2021","journal-title":"Stem Cell. Rep."},{"issue":"5","key":"10.1016\/j.molimm.2026.08.008_bib116","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.clinthera.2016.02.028","article-title":"Key Role of DAMP in Inflammation, Cancer, and Tissue Repair","volume":"38","author":"Pandolfi","year":"2016","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib117","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.molimm.2026.08.008_bib118","unstructured":"PDF) Whole tumor cell vaccine adjuvants: Comparing IL-12 to IL-2 and IL-15 [Internet]. ResearchGate. [cited 2025 Nov 16]. Available from: https:\/\/www.researchgate.net\/publication\/308725229_Whole_tumor_cell_vaccine_adjuvants_Comparing_IL-12_to_IL-2_and_IL-15."},{"issue":"11","key":"10.1016\/j.molimm.2026.08.008_bib119","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.it.2022.09.007","article-title":"Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers","volume":"43","author":"Pinto","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.molimm.2026.08.008_bib120","unstructured":"Precision installation of a highly efficient suicide gene safety switch in human induced pluripotent stem cells - Shi - 2020 - STEM CELLS Translational Medicine - Wiley Online Library [Internet]. [cited 2025 Nov 11]. Available from: https:\/\/stemcellsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/sctm.20-0007."},{"key":"10.1016\/j.molimm.2026.08.008_bib121","doi-asserted-by":"crossref","unstructured":"Predictors of response to immunotherapy in colorectal cancer | The Oncologist | Oxford Academic [Internet]. [cited 2025 Nov 15]. Available from: https:\/\/academic.oup.com\/oncolo\/article\/29\/10\/824\/7699403.","DOI":"10.1093\/oncolo\/oyae152"},{"key":"10.1016\/j.molimm.2026.08.008_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108111","article-title":"The immune modifying effects of chemotherapy and advances in chemo-immunotherapy","volume":"236","author":"Principe","year":"2022","journal-title":"Pharmacol. & Ther."},{"issue":"23","key":"10.1016\/j.molimm.2026.08.008_bib123","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.3390\/cells13231976","article-title":"Advances in Induced Pluripotent Stem Cell-Derived Natural Killer Cell Therapy","volume":"13","author":"Qiao","year":"2024","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.molimm.2026.08.008_bib124","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s12015-020-10042-5","article-title":"Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine","volume":"16","author":"Qiao","year":"2020","journal-title":"Stem Cell. Rev. Rep."},{"key":"10.1016\/j.molimm.2026.08.008_bib125","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/OTT.S500281","article-title":"Progress of Immune Checkpoint Inhibitors Therapy for pMMR\/MSS Metastatic Colorectal Cancer","volume":"17","author":"Qu","year":"2024","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.molimm.2026.08.008_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156268","article-title":"Cytokines and their role as immunotherapeutics and vaccine Adjuvants: The emerging concepts","volume":"169","author":"Rahman","year":"2023","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib127","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12967-020-02306-y","article-title":"Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy","volume":"18","author":"Raza","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.molimm.2026.08.008_bib128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-immunol-051116-052302","article-title":"Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities","volume":"35","author":"Roybal","year":"2017","journal-title":"Annu. Rev. Immunol."},{"issue":"42","key":"10.1016\/j.molimm.2026.08.008_bib129","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/EDBK_349811","article-title":"Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues","author":"Sahin","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-10938-7","article-title":"Long intergenic non-coding RNA 00511 (LINC00511) genetic variations and haplotype implication for colorectal cancer susceptibility and prognosis","volume":"15","author":"Sanad","year":"2025","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.molimm.2026.08.008_bib131","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191369","article-title":"Impact of checkpoint blockade on cancer vaccine\u2013activated CD8+ T cell responses","volume":"217","author":"Santos","year":"2020","journal-title":"J. Exp. Med."},{"issue":"16","key":"10.1016\/j.molimm.2026.08.008_bib132","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.3390\/cancers15164020","article-title":"Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications","volume":"15","author":"Saoudi Gonz\u00e1lez","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.molimm.2026.08.008_bib133","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/cells13020125","article-title":"Interconversion of Cancer Cells and Induced Pluripotent Stem Cells","volume":"13","author":"Sarker","year":"2024","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.molimm.2026.08.008_bib134","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1074\/jbc.R113.509588","article-title":"The Potential for Immunogenicity of Autologous Induced Pluripotent Stem Cell-derived Therapies","volume":"289","author":"Scheiner","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.molimm.2026.08.008_bib135","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","article-title":"Cancer vaccines: Building a bridge over troubled waters","volume":"185","author":"Sellars","year":"2022","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.molimm.2026.08.008_bib136","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41568-022-00497-8","article-title":"Oncofetal reprogramming in tumour development and progression","volume":"22","author":"Sharma","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molimm.2026.08.008_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117858","article-title":"Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy","volume":"184","author":"Sheykhhasan","year":"2025","journal-title":"Biomed. & Pharmacother."},{"issue":"10","key":"10.1016\/j.molimm.2026.08.008_bib138","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/bjs.11204","article-title":"Mechanisms of immunogenicity in colorectal cancer","volume":"106","author":"Sillo","year":"2019","journal-title":"Br. J. Surg."},{"issue":"11","key":"10.1016\/j.molimm.2026.08.008_bib139","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.4049\/jimmunol.166.11.6555","article-title":"Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection1","volume":"166","author":"Soares","year":"2001","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.molimm.2026.08.008_bib140","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12282-020-01079-y","article-title":"Tumor-infiltrating regulatory T cells, CD8\/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer","volume":"27","author":"Solis-Castillo","year":"2020","journal-title":"Breast Cancer"},{"issue":"11","key":"10.1016\/j.molimm.2026.08.008_bib141","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1002\/tcr.202100182","article-title":"The Development of Vaccines from Synthetic Tumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent Immune Response","volume":"21","author":"Stergiou","year":"2021","journal-title":"Chem. Rec."},{"key":"10.1016\/j.molimm.2026.08.008_bib142","doi-asserted-by":"crossref","unstructured":"Steup C., Kennel K.B., Neurath M.F., et al. Current and emerging concepts for systemic treatment of metastatic colorectal cancer. 2025 [cited 2025 Nov 17]; doi: 10.1136\/gutjnl-2025-335412.","DOI":"10.1136\/gutjnl-2025-335412"},{"key":"10.1016\/j.molimm.2026.08.008_bib143","article-title":"Design and immunogenic evaluation of multi-epitope vaccines for colorectal cancer: insights from molecular dynamics and In-Vitro studies","volume":"15","author":"Sun","year":"2025","journal-title":"Front. Oncol. [Internet]"},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib144","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Sig Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12951-024-02311-z","article-title":"The quest for nanoparticle-powered vaccines in cancer immunotherapy","volume":"22","author":"Sun","year":"2024","journal-title":"J. Nanobiotechnology"},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib146","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.molimm.2026.08.008_bib147","unstructured":"Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy | Cellular Oncology [Internet]. [cited 2025 Nov 15]. Available from: https:\/\/link.springer.com\/article\/10.1007\/s13402-025-01051-y."},{"key":"10.1016\/j.molimm.2026.08.008_bib148","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products. Silver Spring, MD: Center for Biologics Evaluation and Research; 2013. Available from: https:\/\/www.fda.gov\/media\/87564\/download."},{"issue":"17","key":"10.1016\/j.molimm.2026.08.008_bib149","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.vaccine.2005.01.015","article-title":"Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits","volume":"23","author":"Uyl-de Groot","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2026.08.008_bib150","unstructured":"Van Damme A. Setting the Standard: The Economic Logic of Industrialized Cell Therapy [Internet]. Cellistic; 2026 [cited 2026 Jul 26]. Available from: https:\/\/www.cellistic.com\/insights\/setting-the-standard-the-economic-logic-of-industrialized-cell-therapy."},{"issue":"48","key":"10.1016\/j.molimm.2026.08.008_bib151","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.3748\/wjg.v24.i48.5418","article-title":"Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens","volume":"24","author":"Wagner","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.molimm.2026.08.008_bib152","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib153","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mdb2.70002","article-title":"Advances and Challenges in Pluripotent Stem Cell-Based Whole-Cell Vaccines for Cancer Treatment","volume":"1","author":"Wan","year":"2025","journal-title":"Med. Bull."},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib154","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3390\/biomedicines13040765","article-title":"Pluripotent Stem Cells: Recent Advances and Emerging Trends","volume":"13","author":"Wang","year":"2025","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib155","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13425","article-title":"Off the shelf\u2019 immunotherapies: Generation and application of pluripotent stem cell-derived immune cells","volume":"56","author":"Wang","year":"2023","journal-title":"Cell. Prolif."},{"key":"10.1016\/j.molimm.2026.08.008_bib156","doi-asserted-by":"crossref","unstructured":"Wang D., Zhang H., Xiang T., et al. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients. Front Immunol [Internet]. 2021 [cited 2025 Nov 15];12.","DOI":"10.3389\/fimmu.2021.762341"},{"issue":"11","key":"10.1016\/j.molimm.2026.08.008_bib157","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14712598.2019.1650909","article-title":"Induced pluripotent stem cells as a novel cancer vaccine","volume":"19","author":"Wang","year":"2019","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.molimm.2026.08.008_bib158","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.molimm.2026.08.008_bib159","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ymthe.2023.06.005","article-title":"An iPSC-derived exosome-pulsed dendritic cell vaccine boosts antitumor immunity in melanoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.molimm.2026.08.008_bib160","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcyt.2025.04.062","article-title":"Evaluating teratoma formation risk of pluripotent stem cell-derived cell therapy products: a consensus recommendation from the Health and Environmental Sciences Institute\u2019s International Cell Therapy Committee","volume":"27","author":"Watanabe","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.molimm.2026.08.008_bib161","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.molimm.2026.08.008_bib162","first-page":"1","article-title":"Development of an inducible caspase-9 safety switch for pluripotent stem cell\u2013based therapies","author":"Wu","year":"2014","journal-title":"Mol. Ther. Methods & Clin. Dev. [Internet]"},{"key":"10.1016\/j.molimm.2026.08.008_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2022.100144","article-title":"Tumor antigens and vaccines in colorectal cancer","volume":"16","author":"Wu","year":"2022","journal-title":"Med. Drug. Discov."},{"issue":"10","key":"10.1016\/j.molimm.2026.08.008_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040","volume":"14","author":"Xi","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.molimm.2026.08.008_bib165","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.molimm.2026.08.008_bib166","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1097\/CM9.0000000000003708","article-title":"Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application","volume":"138","author":"Xie","year":"2025","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib167","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12943-024-02166-w","article-title":"Cellular mechanisms of combining innate immunity activation with PD-1\/PD-L1 blockade in treatment of colorectal cancer","volume":"23","author":"Xie","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.molimm.2026.08.008_bib168","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/sci.2018.07.03","article-title":"Vaccination with induced pluripotent stem cells confers protection against cancer","volume":"5","author":"Yaddanapudi","year":"2018","journal-title":"Stem Cell. Investig."},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib169","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.stem.2020.09.014","article-title":"Pluripotent Stem Cell-Based Cell Therapy\u2014Promise and Challenges","volume":"27","author":"Yamanaka","year":"2020","journal-title":"Cell. Stem Cell."},{"issue":"10","key":"10.1016\/j.molimm.2026.08.008_bib170","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/stcltm\/szae058","article-title":"Detection of residual pluripotent stem cells in cell therapy products utilizing droplet digital PCR: an international multisite evaluation study","volume":"13","author":"Yasuda","year":"2024","journal-title":"Stem Cells Transl. Med."},{"issue":"10","key":"10.1016\/j.molimm.2026.08.008_bib171","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/gm284","article-title":"Transcriptomic analysis of pluripotent stem cells: insights into health and disease","volume":"3","author":"Yeo","year":"2011","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib172","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","article-title":"Exploiting innate immunity for cancer immunotherapy","volume":"22","author":"Yi","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib173","article-title":"Immunization with Embryonic Stem Cells\/Induced Pluripotent Stem Cells Induces Effective Immunity against Ovarian Tumor-Initiating Cells in Mice","volume":"2023","author":"Yu","year":"2023","journal-title":"Stem Cells Int."},{"issue":"2","key":"10.1016\/j.molimm.2026.08.008_bib174","article-title":"Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors","volume":"7","author":"Zhang","year":"2026","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.molimm.2026.08.008_bib175","article-title":"Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib176","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Sig Transduct. Target. Ther."},{"key":"10.1016\/j.molimm.2026.08.008_bib177","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","article-title":"Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.molimm.2026.08.008_bib178","article-title":"Current development and challenges of NK cell-based immunotherapy for gastrointestinal cancers","author":"Zheng","year":"2026","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib179","article-title":"Tumorigenicity risk of iPSCs in vivo: nip it in the bud","volume":"5","author":"Zhong","year":"2022","journal-title":"Prec Clin. Med."},{"key":"10.1016\/j.molimm.2026.08.008_bib180","doi-asserted-by":"crossref","unstructured":"Zhou H., Ma Y., Liu F., et al. Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment. Front Immunol [Internet]. 2023 [cited 2025 Nov 16];14.","DOI":"10.3389\/fimmu.2023.1255799"},{"key":"10.1016\/j.molimm.2026.08.008_bib181","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.molimm.2026.08.008_bib182","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/vaccines13040337","article-title":"The Application of Dendritic Cells Vaccines in Tumor Therapy and Their Combination with Biomimetic Nanoparticles","volume":"13","author":"Zhu","year":"2025","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.molimm.2026.08.008_bib183","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1461","article-title":"Personalised neoantigen-based therapy in colorectal cancer","volume":"13","author":"Zhu","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.molimm.2026.08.008_bib184","first-page":"60","article-title":"iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment","volume":"12","author":"Zong","year":"2025","journal-title":"Bioeng. (Basel)"}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589026001884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589026001884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:03:24Z","timestamp":1788671004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589026001884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":184,"alternative-id":["S0161589026001884"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2026.08.008","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"iPSC-derived polyvalent vaccines as ontogenetically informed immunogens toward overcoming immune refractoriness in microsatellite-stable colorectal cancer: An emerging frontier in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2026.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}